Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma-Reference-Cited by-同舟云学术

Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma

Published:2008-07 Issue:4 Volume:14 Page:782-786
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

LIVNAT T.,MARTINOWITZ U.,ZIVELIN A.,SELIGSOHN U.

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2008.01688.x/fullpdf

Reference8 articles.

1. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors;Schneiderman;Haemophilia,2004

2. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience;Schneiderman;Haemophilia,2007

3. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy;Key;Thromb Haemost,2002

4. Concomitant infusion of low doses of rFVIIa and FEIBA in severe hemophilia A patients with an inhibitor to factor VIII who are refractory to rFVIIa or FEIBA has an excellent hemostatic effect and synergistically enhances thrombin generation;Martinowitz;J Thromb Haemost,2005

5. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI;Livnat;J Thromb Haemost,2006

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global Hemostatic Methods to Tailor Treatment With Bypassing Agents in Hemophilia A With Inhibitors— A Single-Center, Pilot Study;Clinical and Applied Thrombosis/Hemostasis;2024-01

2. Thrombin generation and implications for hemophilia therapies: A narrative review;Research and Practice in Thrombosis and Haemostasis;2023-01

3. Hemophilia A: Emicizumab monitoring and impact on coagulation testing;Advances in Clinical Chemistry;2023

4. Effects of low and high factor X concentrations on thrombin generation in vitro;Thrombosis Update;2022-08

5. Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients;Blood Coagulation & Fibrinolysis;2020-04